Pharma BD Deal Intelligence
A slow-burn collapse: Genentech's CHF 400M (~$418M) anti-tau bet on AC Immune's semorinemab ended an 18-year alliance after semorinemab missed TAURIEL in 2020 and crenezumab failed Phase 2 in 2022, despite semorinemab later showing a 43.6% slowing on ADAS-Cog11 with no functional benefit.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Termination reflected clinical disappointment rather than strategic realignment — semorinemab missed in TAURIEL (2020) and crenezumab failed Phase 2…
Combined crenezumab and semorinemab deals were valued at over $700M; their return ends a multi-program collaboration that had been one of Roche's largest…
Semorinemab demonstrated a 43.6% slowing of decline on ADAS-Cog11 in LAURIET but no benefit on functional outcomes — a mixed signal that proved insufficient to…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Genentech (Roche) and AC Immune exclusive worldwide license/research collaboration for anti-tau antibodies in Alzheimer's. Undisclosed upfront plus up to CHF 400M (~$418M) in research/dev/commercial milestones. Built on prior crenezumab (anti-amyloid) deal from 2006.
$11.3B Global Alzheimer's therapeutics market 2024 · 33.3% Prevalence in Americans 85+
Alzheimer's disease is a progressive neurodegenerative disorder characterized by accumulation of extracellular amyloid-beta plaques and intracellular hyperphosphorylated tau tangles, leading to cortical neuron loss and dementia. It is hard to treat because amyloid-targeted therapies have shown only modest cognitive benefit and tau biology, while more correlated with cognitive decline, has yielded repeated late-stage failures.
The 2012 Genentech/AC Immune anti-tau collaboration sat at the leading edge of an industry pivot away from pure amyloid bets. Competing anti-tau antibody programs at the time and since included AbbVie's tilavonemab (ABBV-8E12, terminated), Biogen/Eisai's BIIB092 gosuranemab (terminated), Lilly's zagotenemab (terminated), UCB/Roche's bepranemab (Phase 2), and JNJ's posdinemab (Phase 2). On the amyloid side, Eisai/Biogen's Leqembi (lecanemab) and Lilly's Kisunla (donanemab) became the first disease-modifying agents approved (2023–2024), reshaping standard of care and reducing the strategic incentive to continue tau monoclonals with mixed data. Semorinemab targeted the N-terminus of all tau isoforms, but TAURIEL (early AD) missed in 2020 and LAURIET (mild-moderate AD) showed a 43.6% slowing on ADAS-Cog11 yet missed functional endpoints, leaving the program neither convincingly positive nor unambiguously failed. The deal terminated in January 2024 when Genentech returned all rights, ending an 18-year alliance that had also covered crenezumab. AC Immune now retains global rights and is positioning the asset as a next-gen reformulation candidate.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / AC Immune SA (this deal) | 2012 | $418M | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2012 deals · Roche Holding AG deals · Neurology deals